mRNA Melanoma Vaccine Combined With Pembrolizumab Reduces Recurrence and Death Risk in Trial
Source Summary
Adjuvant treatment combining the mRNA vaccine intismeran autogene with pembrolizumab (Keytruda) significantly improved recurrence-free survival in patients with resected stage IIB-IV melanoma, according to phase III trial data. The combination therapy showed meaningful clinical benefit in preventing cancer recurrence or death in this patient population.
Why it matters
Positive results from this phase III trial could support regulatory approval of a new treatment option for melanoma patients at high risk of recurrence after surgery.
